glp 1 agonist lilly Drugmaker Eli announced that the FDA approved its daily GLP-1 pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports. https://abcnewslive.visitlink.me/pYGbNh FDA approves Lilly's Foundayo (orforglipron)
Description
doi: 10.3748/wjg.v30.i48.5205 Summary Keywords crp, GLP-1 RA, IL-6, inflammatory biomarker, MDA, T2D, TNF- Citation Alrasheed T, Mostafa MEA, Madkhali MA and Khairy HA (2026) Inflammatory biomarker response to GLP-1 receptor agonists versus other glucose-lowering medications in patients with type 2 diabetes: a systematic review and meta-analysis
NASM, along with other professional organizations, recommends at least 1.6 to 2.2 grams of protein per kilogram of body weight (or 0.73 to 1 gram per pound) for people eating in a deficit
This form is the major active circulating form of GLP-1, whereas GLP-1 (7-37) is less common
The adverse events associated with GLP-1 RA use are generally mild and include nausea and vomiting
Fortunately, the agent itself has an independent effect on curbing alcohol intake and cravings by affecting brain pathways related to reward and addiction
Both are subject to how others perceive them
